Literature DB >> 9404701

Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma.

T Shiozawa1, T Nikaido, M Shimizu, Y Zhai, S Fujii.   

Abstract

BACKGROUND: Abnormalities in G1 cell cycle regulation have been associated with the malignant transformation of cells. To obtain further information about the role of factors regulating the G1 cell cycle in the development of endometrial carcinoma, the authors analyzed the expression of cdk4 (cyclin-dependent kinase) and p16INK4 (an inhibitor of cdk4).
METHODS: Immunohistochemical staining was performed on 20 specimens of normal endometria and 41 specimens of endometrioid-type endometrial carcinoma using antibodies against cdk4 and p16INK4.
RESULTS: In the glandular epithelia of the normal endometria, cytoplasmic staining of cdk4 and p16INK4 was observed only in the proliferative phase, but nuclear staining of these agents was negligible. In endometrial carcinomas, 8 (19.5%) and 14 (34.2%) were positive for cdk4 and p16INK4 in the nucleus, respectively. Topographically, the nuclear cdk4 positive tumor cells were negative for p16INK4 and the nuclear p16INK4 positive tumor cells were found in areas without nuclear cdk4 expression, suggesting an inverse correlation between the two agents. In addition, the poorly differentiated carcinomas were more frequently positive for nuclear cdk4 than were the highly differentiated carcinomas (P = 0.03).
CONCLUSIONS: These data suggest that increased expression of nuclear cdk4 associated with loss of p16INK4 expression could be involved in the carcinogenesis of a subset of endometrial carcinomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404701     DOI: 10.1002/(sici)1097-0142(19971215)80:12<2250::aid-cncr5>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.

Authors:  Yu-Zhen Feng; Tanri Shiozawa; Akiko Horiuchi; Hsien-Chang Shih; Tsutomu Miyamoto; Hiroyasu Kashima; Akihisa Suzuki; Toshio Nikaido; Ikuo Konishi
Journal:  Virchows Arch       Date:  2005-07-14       Impact factor: 4.064

Review 2.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Authors:  Sigurd F Lax
Journal:  Virchows Arch       Date:  2004-01-28       Impact factor: 4.064

3.  Alteration of p16 and p15 genes in human uterine tumours.

Authors:  R Nakashima; M Fujita; T Enomoto; T Haba; K Yoshino; H Wada; H Kurachi; M Sasaki; K Wakasa; M Inoue; G Buzard; Y Murata
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

4.  The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.

Authors:  H Tsuda; K Yamamoto; T Inoue; I Uchiyama; N Umesaki
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

5.  Immunohistochemical characterization of cyclin dependent kinase-4 in different histological grades of oral leukoplakia and oral squamous cell carcinoma.

Authors:  Ndvn Shyam; Nirmala N Rao; Raman Ds Narang; Jiji George; Sanjay R Bommu; G Kiran
Journal:  J Oral Maxillofac Pathol       Date:  2014-01

6.  Epstein-Barr virus and p16INK4A methylation in squamous cell carcinoma and precancerous lesions of the cervix uteri.

Authors:  Na Rae Kim; Zhenhua Lin; Kyong Rae Kim; Hyun Yee Cho; Insun Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

7.  Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.

Authors:  Yuji Ikeda; Katsutoshi Oda; Hideki Ishihara; Osamu Wada-Hiraike; Aki Miyasaka; Tomoko Kashiyama; Kanako Inaba; Tomohiko Fukuda; Kenbun Sone; Yoko Matsumoto; Takahide Arimoto; Daichi Maeda; Masako Ikemura; Masahi Fukayama; Kei Kawana; Tetsu Yano; Daisuke Aoki; Yutaka Osuga; Tomoyuki Fujii
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.